Despite a significant decrease in incidence over the last 70 years, gastric cancer remains a significant health problem worldwide. At the time of diagnosis majority of gastric cancer patients are at the advanced stage. The prognosis is poor due to low resectability at presentation, and high recurrence rate even after curative surgery [1]. Among postoperative failure distant metastasis predominate, however loco-regional relapse is also a major problem. According to some authors, the first site of relapse is local or regional in up to 50% of...

Patient population: From 2014 to 2018, twenty nine consecutive patients (ages 40-75, mean age 58) who underwent CT for the assessment of tumor response of neoadjuvant chemoradiotherapy of gastric cancer were prospectively enrolled in our study. There were 24 patients with locally advanced cancer of the stomach and 5 patients with regional recurrence. Treatment Radiation therapy was delivered with high-energy photons using electron accelerator Philips SL 20. The total dose of 45 Gy, was delivered during 18 days (with the weekends - 24 days), five...

Among the patients with primary gastric cancer (n=24) it is necessary to explore three aspects: symptoms of the tumor response, tumor size and structure. CT allowed very clearly follow the disappearance of intraluminal and extramural components of the tumor, changes in the texture of the tumor, the appearance of the border between the tumor and surrounding organs; reducing the extent of the involvement of the duodenum or the esophagus. On the prechemoradiotherapy CT, two tumors were diagnosed as cT0-3 stage, 22 tumors as cT4. After...

Thus, MDCT significantly improves capability of neoadjuvant therapy response evaluation in patients with gastric cancer. The scope of clinical and instrumental methods completed with MDCT allows approaching an objective quantitative assessment of tumor regression. It is necessary to explore three aspects: symptoms of the tumor response, tumor size and attenuation.

1. Andrew D. Newton, Jashodeep Datta, Arturo Loaiza-Bonilla, Giorgos C. Karakousis, Robert E. Roses Neoadjuvant therapy for gastric cancer: current evidence and future directions. J Gastrointest Oncol.2015;6(5): 534–543.doi:10.3978/j.issn.2078-6891.2015.047. 2. Michele Orditura, Gennaro Galizia, Vincenzo Sforza, Valentina Gambardella, Alessio Fabozzi, Maria Maddalena Laterza, Francesca Andreozzi, Jole Ventriglia, Beatrice Savastano, Andrea Mabilia, Eva Lieto, Fortunato Ciardiello, Ferdinando De Vita Treatment of gastric cancer World J Gastroenterol.2014;20(7): 1635–1649. doi:10.3748/wjg.v20.i7.1635 3. Riccardo Giampieri, Michela Del Prete, Luca Cantini, Maria Giuditta Baleani, Alessandro Bittoni, Elena Maccaroni, Rossana Berardi Optimal management...